WHO ICTRP trial
CLL11 - A study to evaluate the efficacy of Epcoritamab consolidation in high…
ACTRN12625000387426 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12625000387426 |
|---|---|
| Public title | CLL11 - A study to evaluate the efficacy of Epcoritamab consolidation in high genomic risk and Measurable Residual Disease (MRD)-positive Chronic Lymphocytic Leukaemia (CLL) patients after first-line venetoclax and obinutuzumab |
| Scientific title | CLL11 - An ALLG phase II trial of Epcoritamab consolidation in high genomic risk and MRD-positive Chronic Lymphocytic Leukaemia (CLL) patients after first-line venetoclax and obinutuzumab |
| Primary sponsor | Australasian Leukaemia and Lymphoma Group (ALLG) |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 2 |
| Countries | Australia;New Zealand |
| Conditions | Chronic Lymphocytic Leukaemia; Chronic Lymphocytic Leukaemia;Cancer - Leukaemia - Chronic leukaemia |
| Interventions | Epcoritamab is supplied as a concentrate for solution for intended subcutaneous injection. Epcoritamab will be provided by AbbVie as 4mg/0.8mL and 48mg/0.8mL vials. As per standard of care (SOC) practices, patients will receive induction… |
| Registration date | Jan 5, 2025 |
| Target size | 38 |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: